Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus exposure in elderly and obese patients with advanced breast cancer
NL-OMON38713Phase 4Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus and exemestane in breast cancer (3 arms), sponsored by Radboud University Medical Center. Primary endpoints: Effect of old age on everolimus exposure, Effect of obesity on everolimus exposure and 1 more. Started Oct 2013; status: active, not recruiting.
02
Drugs
everolimusexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON38713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38713.